<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03664635</url>
  </required_header>
  <id_info>
    <org_study_id>M-2016-312</org_study_id>
    <nct_id>NCT03664635</nct_id>
  </id_info>
  <brief_title>MB-CART20.1 Lymphoma</brief_title>
  <official_title>A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART20.1 in Patients With Relapsed or Resistant CD20 Positive B-NHL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miltenyi Biomedicine GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Miltenyi Biomedicine GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a phase I/II trial to assess safety, dose finding and feasibility of ex vivo
      generated MB-CART20.1 cells in patients with relapsed or refractory CD20 positive B-NHL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MB-CART20.1 consists of autologous Anti-CD20 Chimeric Antigen Receptor (CAR) transduced CD4
      /CD8 enriched T cells targeting CD20-positive tumor cells in Non-Hodgkin-Lymphoma (NHL)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2018</start_date>
  <completion_date type="Anticipated">November 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I - Determination of the maximum tolerated dose (MTD)</measure>
    <time_frame>until day 28 after infusion of MB-CART20.1</time_frame>
    <description>MTD is defined as the highest dose level at which &lt; 33% of patients experience Dose Limiting Toxicity (DLT). Safety and toxicity assessment of MB-CART20.1 per adverse events (AE) reporting classified according to CTCAE version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II - Best overall response rate</measure>
    <time_frame>3 months after infusion of MB-CART20.1</time_frame>
    <description>Response (Complete response (CR), Partial response (PR), Stable disease (SD), Progressive disease (PD)) is defined according to Cheson criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I - Related safety and toxicity of MB-CART20.1</measure>
    <time_frame>months 3, 6, 9 and 12 after infusion of MB-CART20.1</time_frame>
    <description>Per adverse events (AE) reporting classified according to CTCAE version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I - Best overall response rate over 4 weeks and 3 months</measure>
    <time_frame>4 weeks and 3 months after infusion of MB-CART20.1</time_frame>
    <description>Response (CR, PR, SD and PD) is defined according to Cheson criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I - Best overall response rate over 1 year</measure>
    <time_frame>1 year after infusion of MB-CART20.1</time_frame>
    <description>Response (CR, PR, SD and PD) is defined according to Cheson criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I - Occurrence of B-cell aplasia</measure>
    <time_frame>1 year after infusion of MB-CART20.1</time_frame>
    <description>Circulating B cell numbers in the peripheral blood will be assessed by Flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I - Phenotype and Persistence of MB-CART20.1</measure>
    <time_frame>1 year after infusion of MB-CART20.1</time_frame>
    <description>Blood samples for determination of persistence/phenotyping of infused MB-CART20.1 will be analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - Best overall response rate over 1 year</measure>
    <time_frame>1 year after infusion of MB-CART20.1</time_frame>
    <description>Response (CR, PR, SD and PD) is defined according to Cheson criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - Overall response rate over 4 weeks and 3 months</measure>
    <time_frame>4 weeks and 3 months after infusion of MB-CART20.1</time_frame>
    <description>Response (CR, PR, SD and PD) is defined according to Cheson criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - Overall response rate over 1 year</measure>
    <time_frame>1 year after infusion of MB-CART20.1</time_frame>
    <description>Response (CR, PR, SD and PD) is defined according to Cheson criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - Number of patients with CR, PR, SD and PD</measure>
    <time_frame>1 year after infusion of MB-CART20.1</time_frame>
    <description>Response (CR, PR, SD and PD) is defined according to Cheson criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II -Percentage of patients with CR, PR, SD and PD</measure>
    <time_frame>1 year after infusion of MB-CART20.1</time_frame>
    <description>Response (CR, PR, SD and PD) is defined according to Cheson criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - Safety and toxicity assessment of MB-CART20.1</measure>
    <time_frame>1 year after infusion of MB-CART20.1</time_frame>
    <description>Per adverse events (AE) reporting classified according to CTCAE version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - Occurrence of B-cell aplasia</measure>
    <time_frame>1 year after infusion of MB-CART20.1</time_frame>
    <description>Circulating B cell numbers in the peripheral blood will be assessed by Flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II - Phenotype and Persistence of MB-CART20.1</measure>
    <time_frame>1 year after infusion of MB-CART20.1</time_frame>
    <description>Blood samples for determination of persistence/phenotyping of infused MB-CART20.1 will be analysed.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>B-cell Lymphoma Refractory</condition>
  <condition>B-cell Lymphoma Recurrent</condition>
  <arm_group>
    <arm_group_label>Phase I - Safety Dose Level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In phase I three (3) + 3 patients will be treated with 1x10^5 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the preceding safety dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In phase I six (6) + 3 patients will be treated with 1x10^6 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In phase I six (6) + 3 patients will be treated with 3x10^6 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The number of additional patients who will be treated with MB-CART20.1 cells in Phase II is depending on the number of evaluable patients treated with the maximum tolerated dose (MTD) level and the results in Part I</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MB-CART20.1</intervention_name>
    <description>MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL</description>
    <arm_group_label>Phase I - Dose Level 1</arm_group_label>
    <arm_group_label>Phase I - Dose Level 2</arm_group_label>
    <arm_group_label>Phase I - Safety Dose Level</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>CD20-targeting CAR T Cells</other_name>
    <other_name>Anti-CD20 CAR T cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory/relapsed CD20+ B-NHL (including malignant transformation like Richter's
             transformation) with no curative treatment option.

          -  At least 18 years of age

          -  Estimated life expectancy of more than 3 months

          -  ECOG performance status (Eastern cooperative oncology group) of 0-2

          -  Negative serological HBV (Hepatitis B virus) test, negative testing of HCVAb
             (Hepatitis C virus Antibody), negative HIV1/2 (Human immunodeficiency virus 1/2 ) test
             within 6 weeks prior to enrollment

          -  No childbearing potential or negative pregnancy test at screening and before
             chemotherapy in women with childbearing potential.

          -  Signed and dated informed consent before conduct of any trial-specific procedure

        Exclusion Criteria:

          -  Participation in another interventional trial that could interact with this trial

          -  Any evidence 0f CNS (Central nervous system) involvement

          -  Known history or presence of clinically relevant CNS pathology

          -  Patients with history of primary immunodeficiency,

          -  Patients with any history of auto-immune induced condition such as those caused by
             checkpoint inhibitors, MEK inhibitors or BRAF inhibitors, for example pituitary
             hypophysitis must be excluded

          -  Patients with Chronic Lymphocytic Leukemia unless suffering from malignant
             transformation

          -  Active systemic fungal, viral or bacterial infection

          -  Serious cardiac functional incapacity (class III or IV as defined by the New York
             Heart Association Classification)

          -  Severe pulmonary disease (DLCO (Transfer factor of the lung for carbon monoxide)
             and/or FEV1 (Forced expiratory volume in 1 second) &lt; 65%, dyspnea at rest)

          -  Liver dysfunction as indicated by a total bilirubin, AST (Aspartate Aminotransferase),
             and ALT (Alanine aminotransferase) ≥ 2 the institutional ULN (Upper limit of normal)
             value, unless directly attributable to the patient's tumor

          -  Creatinine clearance &lt;50 ml/min calculated according to the modified formula of
             Cockcroft and Gault

          -  Pregnant or lactating women

          -  Active secondary malignancy requiring treatment (except basal cell carcinoma or
             malignant tumor curatively treated by surgery) within the last 5 years before
             enrollment.

          -  Medical condition requiring prolonged use of systemic corticosteroids (&gt; 1 month)

          -  Prior therapy with genetically modified substances

          -  Use of anti-CD20 antibodies within 4 weeks before leukapheresis

          -  Chemotherapy within 4 weeks prior to leukapheresis

          -  Other treatment within 4 weeks or two half-lives, whichever is longer before
             MB-CART20.1 infusion. This pertains to immunomodulatory therapies such as checkpoint
             inhibitors because of the influence on the immune system

          -  Concurrent systemic radiotherapy

          -  Hypersensitivity against any drug or its ingredients/impurities that is scheduled or
             likely to be given during trial participation e.g. as part of the mandatory
             lymphodepletion protocol, pre-medication for infusion, rescue medication/salvage
             therapies for treatment of related toxicities

          -  Patients in which such medication is contraindicated for other reasons than
             hypersensitivity (e.g. live vaccines and fludarabine)

          -  Patients in which trial related procedures are contraindicated as judged by the
             investigator, e.g. lumbar punctures for CSF (Cerebrospinal fluid) sampling

          -  Patient's lack of accountability, inability to appreciate the nature, meaning and
             consequence of the trial and to formulate his/her own wishes correspondingly

          -  Patients who have a relationship of dependence or employer employee relationship to
             the sponsor or the investigator

          -  Committal to an institution on judicial or official order

          -  Cerebral dysfunction, legal incapacity

          -  Other investigational treatment within 4 weeks before IMP (Investigational Medicinal
             Product) infusion

          -  Clinically relevant autoimmune diseases or history of autoimmune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Borchmann, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Köln</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Schubert</last_name>
    <phone>+49 2204 8306 6564</phone>
    <email>christines@miltenyibiotec.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Karitzky, Dr.</last_name>
    <phone>+49 2204 8306 6560</phone>
    <email>sandrak@miltenyibiotec.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Cologne - Clinic for Internal Medicine I</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Borchmann, Prof. Dr.</last_name>
      <phone>+49 (0) 221 478-88159</phone>
      <email>peter.borchmann@uni-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklikum Leipzig, AöR</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vladan Vucinic, Dr.</last_name>
      <phone>+49 341 97-13141</phone>
      <email>vladan.vucinic@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Georg-Nikolaus Franke, Dr.</last_name>
      <email>georg-nikolaus.franke@medizin.uni-leipzig.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 3, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>March 6, 2019</last_update_submitted>
  <last_update_submitted_qc>March 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

